BGDV - ETF AI Analysis
Top Page
Bahl & Gaynor Dividend ETF (BGDV)
Rating:74Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has delivered solid gains so far this year, showing positive momentum for investors.
High-Quality Top Holdings
Many of the largest positions, including major technology and health care names, have shown strong or steady performance, helping support the fund’s returns.
Broad Sector Diversification
Holdings spread across technology, industrials, financials, health care, energy, and other sectors help reduce the impact if any one industry struggles.
Negative Factors
Moderately High Expense Ratio
The fund’s fees are higher than many low-cost index ETFs, which can slightly reduce long-term returns.
Heavy U.S. Market Focus
With almost all assets in U.S. companies, investors get little geographic diversification and remain highly tied to the U.S. economy.
Concentration in a Few Large Positions
A small group of top holdings makes up a meaningful share of the portfolio, increasing the impact if any of these companies run into trouble.
BGDV vs. SPDR S&P 500 ETF (SPY)
AUM791.09M
RegionNorth America
Expense Ratio0.45%
Beta0.76
IssuerBahl & Gaynor
Inception DateDec 11, 2024
Dividend Yield1%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,904
30 Day Avg. Volume11,727
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
36.66Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering47
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BGDV Summary
The Bahl & Gaynor Dividend ETF (BGDV) is a U.S.-focused fund that invests across the total stock market, but with a special focus on companies that pay dividends. It doesn’t track a single index; instead, managers choose a mix of businesses from many sectors, including technology, industrials, and financials. Well-known holdings include Alphabet (Google’s parent company) and Broadcom. Someone might invest in BGDV to seek a blend of income from dividends and long-term growth, while staying diversified across many industries. A key risk is that stock prices and dividend payments can still go up and down with the overall market.
How much will it cost me?The Bahl & Gaynor Dividend ETF (BGDV) has an expense ratio of 0.45%, which means you’ll pay $4.50 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, meaning investment professionals select stocks rather than following a preset index. Active management often comes with higher costs due to the additional research and expertise involved.
What would affect this ETF?The Bahl & Gaynor Dividend ETF (BGDV), with its focus on dividend-paying stocks across sectors like technology, financials, and health care, could benefit from economic stability and growth, as well as increased demand for income-generating investments during periods of low interest rates. However, it may face challenges from sector-specific risks, such as regulatory changes in technology or health care, and broader economic downturns that could impact dividend payouts. Its heavy exposure to U.S. markets also makes it sensitive to domestic economic conditions and policy shifts.
BGDV Top 10 Holdings
BGDV is quietly leaning on a mix of U.S. dividend-heavy tech and health names, with TSM and Broadcom acting as the fund’s semiconductor engine. TSM has been rising this year, helping drive returns, while Broadcom’s more mixed, recently lagging performance has taken a bit of shine off the tech sleeve. Victory Capital and Motorola Solutions have been steady climbers, giving the fund a solid industrial and financial backbone. On the healthcare side, Eli Lilly and AbbVie are contributing, but with a more measured, stop-and-go pace. Overall, it’s a U.S.-centric, dividend-focused story with a noticeable tilt toward tech and healthcare leaders.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| TSMC | 5.37% | $42.59M | $1.97T | 67.06% | 81 Outperform | |
| Broadcom | 4.40% | $34.92M | $1.73T | 0.59% | 76 Outperform | |
| Victory Capital Holdings | 3.89% | $30.83M | $6.78B | 60.74% | 80 Outperform | |
| Eli Lilly & Co | 3.56% | $28.26M | $1.05T | 47.70% | 72 Outperform | |
| Motorola Solutions | 3.32% | $26.35M | $77.15B | -3.23% | 70 Neutral | |
| AbbVie | 3.17% | $25.14M | $454.36B | 17.76% | 66 Neutral | |
| UnitedHealth | 2.94% | $23.29M | $340.27B | 7.54% | 72 Outperform | |
| Amphenol | 2.86% | $22.65M | $206.94B | 41.42% | 78 Outperform | |
| Alphabet Class A | 2.82% | $22.35M | $4.12T | 40.57% | 85 Outperform | |
| Encompass Health | 2.79% | $22.14M | $12.01B | -3.44% | 64 Neutral |
BGDV Technical Analysis
Negative
―
Price Trends
31.12
Negative
30.68
Negative
29.36
Positive
Market Momentum
-0.21
Positive
29.35
Positive
10.52
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BGDV, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 30.95, equal to the 50-day MA of 31.12, and equal to the 200-day MA of 29.36, indicating a neutral trend. The MACD of -0.21 indicates Positive momentum. The RSI at 29.35 is Positive, neither overbought nor oversold. The STOCH value of 10.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BGDV.
BGDV Peer Comparison
Comparison Results
Performance Comparison
BGDV
Bahl & Gaynor Dividend ETF
30.18
3.66
13.80%
AVTM
Avantis Total Equity Markets ETF
―
―
―
ULTY
YieldMax Ultra Option Income Strategy ETF
―
―
―
XCHG
AB US Equity ETF
―
―
―
SMRI
Bushido Capital US Equity ETF
―
―
―
EBI
Longview Advantage ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents